Financial Ratios Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.980 USD | +1.71% |
|
+1.02% | +8.36% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -5.43 | -6.85 | -32.81 | -19.02 | -23.34 | |||||
Return on Total Capital | -5.74 | -7.11 | -38.66 | -22.42 | -28.11 | |||||
Return On Equity % | -9.26 | -11.3 | -57.7 | -42.82 | -41.65 | |||||
Return on Common Equity | -9.27 | -11.3 | -57.7 | -42.82 | -41.65 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 50.94 | 23 | 100 | -2.61K | -9.43K | |||||
SG&A Margin | 70.93 | 200.08 | 1.47K | 1.83K | 3.42K | |||||
EBITDA Margin % | -32.1 | -208.87 | -2.79K | -4.44K | -12.48K | |||||
EBITA Margin % | -33.58 | -212.75 | -2.85K | -4.59K | -12.85K | |||||
EBIT Margin % | -34.19 | -213.71 | -2.86K | -4.59K | -12.85K | |||||
Income From Continuing Operations Margin % | -33.69 | -206.5 | -2.61K | -5.39K | -11.72K | |||||
Net Income Margin % | -33.69 | -206.5 | -3.24K | -5.45K | -11.67K | |||||
Net Avail. For Common Margin % | -33.72 | -206.5 | -2.61K | -5.39K | -11.72K | |||||
Normalized Net Income Margin | -21 | -123.7 | -1.75K | -2.42K | -7.38K | |||||
Levered Free Cash Flow Margin | -20.64 | -27.73 | -576.82 | -5.75K | -6.83K | |||||
Unlevered Free Cash Flow Margin | -20.64 | -27.73 | -573.16 | -5.75K | -6.8K | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.25 | 0.16 | 0.02 | 0.01 | 0 | |||||
Fixed Assets Turnover | 3.68 | 4.14 | 0.43 | 0.04 | 0.01 | |||||
Receivables Turnover (Average Receivables) | 4.96 | 5.96 | 1.13 | 2.27 | 14.49 | |||||
Inventory Turnover (Average Inventory) | 6.07 | 5.2 | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 37.37 | 19.89 | 1.07 | 12.68 | 5.17 | |||||
Quick Ratio | 36.58 | 16.86 | 0.66 | 12.53 | 5.08 | |||||
Operating Cash Flow to Current Liabilities | -1.58 | -4.55 | -2.36 | -1 | -2.88 | |||||
Days Sales Outstanding (Average Receivables) | 73.65 | 61.22 | 321.73 | 161.23 | 25.19 | |||||
Days Outstanding Inventory (Average Inventory) | 60.13 | 70.18 | - | - | - | |||||
Average Days Payable Outstanding | 47.96 | 46.93 | - | 75.43 | 65.35 | |||||
Cash Conversion Cycle (Average Days) | 85.82 | 84.46 | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.15 | 0.72 | 3.39 | 1.4 | 1.57 | |||||
Total Debt / Total Capital | 1.14 | 0.71 | 3.28 | 1.38 | 1.55 | |||||
LT Debt/Equity | 0.78 | 0.21 | 3.27 | 1.05 | 1.24 | |||||
Long-Term Debt / Total Capital | 0.77 | 0.21 | 3.16 | 1.04 | 1.22 | |||||
Total Liabilities / Total Assets | 4.27 | 5.94 | 23.2 | 14.79 | 22.45 | |||||
EBIT / Interest Expense | - | - | -487.39 | -1.39K | -302.03 | |||||
EBITDA / Interest Expense | - | - | -474.56 | -1.33K | -290.48 | |||||
(EBITDA - Capex) / Interest Expense | - | - | -487.32 | -2.46K | -324.39 | |||||
Total Debt / EBITDA | -0.27 | -0.03 | -0.06 | -0.06 | -0.03 | |||||
Net Debt / EBITDA | 21.57 | 2.92 | 0.17 | 3.5 | 1.3 | |||||
Total Debt / (EBITDA - Capex) | -0.23 | -0.03 | -0.06 | -0.03 | -0.03 | |||||
Net Debt / (EBITDA - Capex) | 19.08 | 2.86 | 0.16 | 1.89 | 1.16 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 3.85 | 7.38 | -73.52 | 1.39 | -39.2 | |||||
Gross Profit, 1 Yr. Growth % | -0.06 | -9.86 | -39.42 | 100.83 | 107.37 | |||||
EBITDA, 1 Yr. Growth % | -1.32 | 119.31 | 371.34 | 60.34 | 71.04 | |||||
EBITA, 1 Yr. Growth % | -1.2 | 116.97 | 367.76 | 63.15 | 70.01 | |||||
EBIT, 1 Yr. Growth % | -1.12 | 115.04 | 365.34 | 63.15 | 70.01 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -1.71 | 114.7 | 341.43 | 109.13 | 32.31 | |||||
Net Income, 1 Yr. Growth % | -1.71 | 114.7 | 332.23 | 70.46 | 30.07 | |||||
Normalized Net Income, 1 Yr. Growth % | -1.97 | 115.28 | 390.29 | 40.47 | 85.36 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -36.16 | 56.88 | 134.32 | -13.12 | 15.48 | |||||
Accounts Receivable, 1 Yr. Growth % | -1.52 | -20.12 | -14.53 | -90.04 | -94.83 | |||||
Inventory, 1 Yr. Growth % | 51.94 | 42.45 | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -0.37 | -8.73 | 1.6K | 841.58 | 31.18 | |||||
Total Assets, 1 Yr. Growth % | 709.47 | -8.49 | 68.51 | 248.45 | -21.73 | |||||
Tangible Book Value, 1 Yr. Growth % | 1.1K | -9.08 | -98.6 | 31.44K | -30.6 | |||||
Common Equity, 1 Yr. Growth % | 1.08K | -9.09 | 37.58 | 286.63 | -28.77 | |||||
Cash From Operations, 1 Yr. Growth % | -22.08 | 171.77 | 254.9 | -50.44 | 350.88 | |||||
Capital Expenditures, 1 Yr. Growth % | 39.56 | -30.18 | 280.14 | 4.98K | -76.57 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -21.53 | 44.25 | - | 879.9 | -27.83 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -21.53 | 44.25 | - | 885.47 | -28.09 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 17.24 | 5.6 | - | -48.18 | -21.49 | |||||
Gross Profit, 2 Yr. CAGR % | 29.64 | -5.09 | - | 300.54 | 109.93 | |||||
EBITDA, 2 Yr. CAGR % | -20.26 | 47.11 | - | 175.82 | 65.6 | |||||
EBITA, 2 Yr. CAGR % | -19.51 | 46.41 | - | 176.37 | 66.55 | |||||
EBIT, 2 Yr. CAGR % | -19.3 | 45.82 | - | 175.54 | 66.55 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -18.86 | 45.27 | - | 203.84 | 66.34 | |||||
Net Income, 2 Yr. CAGR % | -18.86 | 45.27 | - | 171.44 | 48.91 | |||||
Normalized Net Income, 2 Yr. CAGR % | -19.15 | 45.27 | - | 162.44 | 61.36 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -34.84 | 0.08 | - | 42.68 | 0.16 | |||||
Accounts Receivable, 2 Yr. CAGR % | 32.07 | -11.3 | - | -70.83 | -92.82 | |||||
Inventory, 2 Yr. CAGR % | 35.98 | 47.12 | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.16 | -4.64 | - | 1.17K | 251.44 | |||||
Total Assets, 2 Yr. CAGR % | 173.38 | 172.17 | - | 142.32 | 65.14 | |||||
Tangible Book Value, 2 Yr. CAGR % | 199.14 | 230.95 | - | 109.91 | 1.38K | |||||
Common Equity, 2 Yr. CAGR % | 196.26 | 227.22 | - | 130.64 | 65.95 | |||||
Cash From Operations, 2 Yr. CAGR % | -25.04 | 45.52 | - | 32.62 | 49.48 | |||||
Capital Expenditures, 2 Yr. CAGR % | -7.37 | -1.29 | - | 1.29K | 244.86 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -25.98 | 6.39 | - | - | 165.93 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -25.98 | 6.39 | - | - | 166.21 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 19.28 | 13.86 | - | - | -45.35 | |||||
Gross Profit, 3 Yr. CAGR % | 40.61 | 14.85 | - | - | 227.74 | |||||
EBITDA, 3 Yr. CAGR % | -21.16 | 11.72 | - | - | 135.21 | |||||
EBITA, 3 Yr. CAGR % | -20.28 | 12.02 | - | - | 135.05 | |||||
EBIT, 3 Yr. CAGR % | -20.06 | 11.88 | - | - | 134.58 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -20.34 | 12.23 | - | - | 130.3 | |||||
Net Income, 3 Yr. CAGR % | -20.34 | 12.23 | - | - | 112.41 | |||||
Normalized Net Income, 3 Yr. CAGR % | -20.41 | 12.06 | - | - | 133.72 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -35.5 | -12.67 | - | - | 32.97 | |||||
Accounts Receivable, 3 Yr. CAGR % | 19.08 | 11.69 | - | - | -83.61 | |||||
Inventory, 3 Yr. CAGR % | 25.65 | 38.1 | - | - | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 27.64 | 15.64 | - | - | 494.87 | |||||
Total Assets, 3 Yr. CAGR % | 111.39 | 89.82 | - | - | 66.26 | |||||
Tangible Book Value, 3 Yr. CAGR % | 140.57 | 101.13 | - | - | 45.15 | |||||
Common Equity, 3 Yr. CAGR % | 137.53 | 99.82 | - | - | 55.9 | |||||
Cash From Operations, 3 Yr. CAGR % | -20.81 | 15.16 | - | - | 99.42 | |||||
Capital Expenditures, 3 Yr. CAGR % | 4.18 | -15.7 | - | - | 256.24 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -17.89 | -7.55 | - | - | - | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -17.89 | -7.55 | - | - | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 16.08 | 17.79 | - | - | - | |||||
Gross Profit, 5 Yr. CAGR % | 108.81 | 40.67 | - | - | - | |||||
EBITDA, 5 Yr. CAGR % | -7.63 | 2.75 | - | - | - | |||||
EBITA, 5 Yr. CAGR % | -8.52 | 3.24 | - | - | - | |||||
EBIT, 5 Yr. CAGR % | -8.86 | 3.22 | - | - | - | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -6.39 | 3.37 | - | - | - | |||||
Net Income, 5 Yr. CAGR % | -6.39 | 3.37 | - | - | - | |||||
Normalized Net Income, 5 Yr. CAGR % | -7.89 | 3.36 | - | - | - | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -17.58 | -14.52 | - | - | - | |||||
Accounts Receivable, 5 Yr. CAGR % | 27.18 | 17.24 | - | - | - | |||||
Inventory, 5 Yr. CAGR % | 24.02 | 34.01 | - | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 36.42 | 18.74 | - | - | - | |||||
Total Assets, 5 Yr. CAGR % | 31.22 | 39.34 | - | - | - | |||||
Tangible Book Value, 5 Yr. CAGR % | 32.86 | 42.61 | - | - | - | |||||
Common Equity, 5 Yr. CAGR % | 32.67 | 42.03 | - | - | - | |||||
Cash From Operations, 5 Yr. CAGR % | -6.09 | 6.18 | - | - | - | |||||
Capital Expenditures, 5 Yr. CAGR % | -4.47 | -13.49 | - | - | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -3.22 | -5.84 | - | - | - | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -3.21 | -5.84 | - | - | - |
- Stock Market
- Stocks
- CATX Stock
- Financials Perspective Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















